Research Analysts Set Expectations for HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Zacks Research decreased their Q1 2025 earnings per share estimates for Halozyme Therapeutics in a report released on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.93. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' FY2027 earnings at $7.49 EPS.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

A number of other research firms have also commented on HALO. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Remove Ads

Halozyme Therapeutics Stock Up 1.1 %

Shares of Halozyme Therapeutics stock traded up $0.68 on Thursday, reaching $62.95. The company's stock had a trading volume of 1,587,009 shares, compared to its average volume of 1,304,158. The company has a market capitalization of $7.75 billion, a price-to-earnings ratio of 18.35, a P/E/G ratio of 0.42 and a beta of 1.32. The firm's fifty day simple moving average is $57.05 and its two-hundred day simple moving average is $54.63. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock valued at $1,754,451. Company insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently made changes to their positions in HALO. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.